Edition:
India

Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

859.80INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
Rs869.70
52-wk Low
Rs790.10

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: --
Market Cap(Mil.): Rs357,955.91
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 29.18 29.98
EPS (TTM): -19.13 -- --
ROI: -- 13.62 13.13
ROE: -- 14.52 14.27

UPDATE 1-India's Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

* Mohali was one of the plants Sun gained through Ranbaxy deal

14 Mar 2017

Mylan agreed to pay $96.5 million in Provigil antitrust class action

Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

07 Feb 2017

UPDATE 1-Mylan agreed to pay $96.5 mln in Provigil antitrust class action

Feb 6 Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

07 Feb 2017

Mylan agreed to pay $96.5 mln in Provigil antitrust class action

Feb 6 Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon.

06 Feb 2017

U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial

Nov 21 A U.S. appeals court upheld AstraZeneca Plc and Ranbaxy Laboratories' victory in a lawsuit accusing them of reaching an illegal deal to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium.

22 Nov 2016

BRIEF-Sun Pharmaceutical Industries on track to achieve benefits from Ranbaxy acquisition

* Sun Pharmaceutical Industries Ltd says synergies from the Ranbaxy acquisition are gaining momentum and co on track to achieve the targeted benefits

10 Nov 2016

More From Around the Web

Earnings vs. Estimates